A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) C07K 16/28 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2538229
The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that the activity of CD99, an adhesion molecule known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. Inhibition of the activity of CD99 is predicted to alleviate the symptoms of rheumatoid arthritis.
L'invention porte sur de nouvelles méthodes de traitement de la polyarthrite rhumatoïde et de ses symptômes, et sur de nouveaux procédés d'identification et de criblage de médicaments utiles dans le traitement de la polyarthrite rhumatoïde et de ses symptômes cliniques. Une manipulation ciblée d'un modèle informatisé d'un rhumatisme articulaire chez l'homme ayant permis d'obtenir un résultat surprenant relatif à l'activité de CD99, une molécule d'adhésion connue pour avoir un effet sur certains cancers, a un impact considérable sur la pathophysiologie de la polyarthrite rhumatoïde. Il s'avère que l'inhibition de l'activité de CD99 soulagerait les symptômes de la polyarthrite rhumatoïde.
Hurez Vincent Jacques
Michelson Seth G.
Scherrer Didier A.
Wennerberg Leif Gustaf
Entelos Inc.
Smart & Biggar
LandOfFree
Treatment of rheumatoid arthritis with cd99 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of rheumatoid arthritis with cd99 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of rheumatoid arthritis with cd99 antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1801878